This 2023 statement updates clinical guidance for homozygous familial
hypercholesterolaemia (HoFH), explains the genetic complexity, and provides pragmatic …

This contemporary, international, evidence-informed guidance aims to achieve the greatest
good for the greatest number of people with familial hypercholesterolaemia (FH) across …

Lipids are insoluble in water and therefore cholesterol and triglycerides need to be
transported in association with proteins (ie, lipoproteins) in the bloodstream. Lipoproteins …

Lipid disorders involving derangements in serum cholesterol, triglycerides, or both are
commonly encountered in clinical practice and often have implications for cardiovascular …

The 2021 guidelines primary panel selected clinically relevant questions and produced
updated recommendations, on the basis of important new findings that have emerged since …

Importance Familial hypercholesterolemia (FH) is an underdiagnosed and undertreated
genetic disorder that leads to premature morbidity and mortality due to atherosclerotic …

Optimal care for familial hypercholesterolaemia (FH) requires patient-centred management,
multidisciplinary teamwork, involvement of primary care practitioners, patient networks …

Familial hypercholesterolaemia (FH) is a dominant and highly penetrant monogenic
disorder present from birth that markedly elevates plasma low-density lipoprotein (LDL) …

There is compelling evidence that the elevated plasma lipoprotein (a)[Lp (a)] levels increase
the risk of atherosclerotic cardiovascular disease (ASCVD) in the general population. Like …

Objective: Familial hypercholesterolemia (FH) is associated with a high risk of premature
atherosclerotic cardiovascular disease (ASCVD). However, this risk is highly heterogeneous …